Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • المؤلفون: Lu H;Lu H; Geng da Y; Shen F; Zhang JY; Lu B; Ma LX
  • المصدر:
    Virology journal [Virol J] 2011 Sep 21; Vol. 8, pp. 444. Date of Electronic Publication: 2011 Sep 21.
  • نوع النشر :
    Journal Article; Research Support, Non-U.S. Gov't
  • اللغة:
    English
  • معلومة اضافية
    • المصدر:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101231645 Publication Model: Electronic Cited Medium: Internet ISSN: 1743-422X (Electronic) Linking ISSN: 1743422X NLM ISO Abbreviation: Virol J Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: [London] : BioMed Central, 2004-
    • الموضوع:
      Adenine/*analogs & derivatives ; Alanine Transaminase/*analysis ; Antiviral Agents/*administration & dosage ; Hepatitis B virus/*drug effects ; Hepatitis B, Chronic/*drug therapy ; Hepatitis B, Chronic/*immunology ; Organophosphonates/*administration & dosage; Adenine/administration & dosage ; Adenine/therapeutic use ; Adult ; Alanine Transaminase/metabolism ; Antiviral Agents/therapeutic use ; Biomarkers/analysis ; China ; Female ; Follow-Up Studies ; Hepatitis B Surface Antigens/analysis ; Hepatitis B Surface Antigens/immunology ; Hepatitis B e Antigens/analysis ; Hepatitis B e Antigens/immunology ; Hepatitis B virus/genetics ; Hepatitis B virus/immunology ; Hepatitis B, Chronic/diagnosis ; Hepatitis B, Chronic/metabolism ; Hepatitis B, Chronic/virology ; Humans ; Male ; Organophosphonates/therapeutic use ; Prospective Studies ; Treatment Outcome
    • نبذة مختصرة :
      Background: Adefovir Dipivoxil (ADV) is an important agent to suppress hepatitis B virus (HBV) replication with suboptimal effect on virological and serological response. To optimize Adefovir therapy in chronic hepatitis B (CHB) patients with hepatitis B e antigen (HBeAg) positive, we studied the baseline parameters and on-treatment HBV DNA for favorable outcomes.
      Methods: 48 patients were enrolled in the study and followed up for 5 years prospectively. Baseline characteristics, virological, serological and biochemical parameters as well as on treatment HBV DNA were assessed in prediction of favorable outcomes.
      Results: 1. The patients with baseline alanine aminotransferase (ALT) ≥5 × the upper limit of normal (ULN, 40 IU/L) had higher rates of viral response (VR), HBeAg loss and HBeAg seroconversion at year 5 compared to the patients with ALT < 5 × ULN (VR: 75% vs 43.8%, p = 0.035; HBeAg loss: 43.9% vs 13.8%, p = 0.017; HBeAg seroconversion: 37.9% vs 13.8%, p = 0.035); Patients with baseline HBV DNA < 10(9) copies/ml and ALT ≥3 × ULN had more chance of HBeAg seroconversion (40.9% vs 8.7%, p = 0.012), while in patients with HBeAg < 800 s/co or HBsAg < 5000 IU/ml higher rates of HBeAg loss were achieved. 2. HBV DNA level < 10(4) copies/ml at week 24 was predictive for VR (96.0% vs 40.9%, P < 0.001), HBeAg loss (84.0% vs 36.3%, P = 0.001) and HBeAg seroconversion (36.0% vs 9.1%, P = 0.030).
      Conclusions: ADV treatment should be started for patients with baseline ALT≥5 × ULN or patients with ALT≥3 × ULN and HBV DNA < 10(9) copies/ml. Lower level of HBeAg(< 800 s/co) and HBsAg(< 5000 IU/ml) may be regarded as referenced factors. In patients with serum HBV DNA < 10(4) copies/ml at week 24 the therapy should continue, and a favorable outcome may be achieved in 5 years or longer.
    • References:
      Gut. 2007 May;56(5):699-705. (PMID: 17127704)
      Hepatology. 2009 Sep;50(3):661-2. (PMID: 19714720)
      Hepatology. 2008 Sep;48(3):750-8. (PMID: 18752330)
      Antivir Ther. 2009;14(5):679-85. (PMID: 19704171)
      Antivir Ther. 2007;12(3):355-62. (PMID: 17591025)
      Antivir Ther. 2009;14(1):13-22. (PMID: 19320233)
      Hepatology. 1989 Aug;10(2):198-202. (PMID: 2663695)
      Hepatology. 2007 Jul;46(1):254-65. (PMID: 17596850)
      N Engl J Med. 2004 Oct 7;351(15):1521-31. (PMID: 15470215)
      Rev Esp Enferm Dig. 2009 Nov;101(11):763-7. (PMID: 20001153)
      Clin Gastroenterol Hepatol. 2008 Dec;6(12):1315-41; quiz 1286. (PMID: 18845489)
      J Hepatol. 2009 Jul;51(1):11-20. (PMID: 19345439)
      Gut. 2003 Mar;52(3):416-9. (PMID: 12584226)
      Am J Med. 2004 Jun 15;116(12):829-34. (PMID: 15178498)
      N Engl J Med. 2003 Feb 27;348(9):808-16. (PMID: 12606735)
      Liver Int. 2005 Jun;25(3):472-89. (PMID: 15910483)
      Hepatology. 2010 Jun;51(6):1933-44. (PMID: 20512987)
      Hepatology. 1999 Sep;30(3):770-4. (PMID: 10462384)
      Hepatogastroenterology. 2009 May-Jun;56(91-92):813-8. (PMID: 19621708)
      N Engl J Med. 2005 Jun 30;352(26):2682-95. (PMID: 15987917)
      Am J Gastroenterol. 2007 Dec;102(12):2718-23. (PMID: 17662102)
      Hepatology. 2008 Feb;47(2):428-34. (PMID: 18220290)
      Hepatology. 2009 Apr;49(4):1141-50. (PMID: 19338056)
      J Viral Hepat. 2009 Mar;16(3):203-13. (PMID: 19175871)
      J Viral Hepat. 2009 Feb;16(2):113-20. (PMID: 19175883)
    • الرقم المعرف:
      0 (Antiviral Agents)
      0 (Biomarkers)
      0 (Hepatitis B Surface Antigens)
      0 (Hepatitis B e Antigens)
      0 (Organophosphonates)
      EC 2.6.1.2 (Alanine Transaminase)
      JAC85A2161 (Adenine)
      U6Q8Z01514 (adefovir dipivoxil)
    • الموضوع:
      Date Created: 20110923 Date Completed: 20120112 Latest Revision: 20211020
    • الموضوع:
      20231215
    • الرقم المعرف:
      PMC3205069
    • الرقم المعرف:
      10.1186/1743-422X-8-444
    • الرقم المعرف:
      21936898